Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 151 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: HDL Clear all

Conditions: Cardiovascular Disease
Interventions: Soy Protein Powder (25g/d), Placebo, Soy Protein Powder (50g/d); Dietary Supplement
Lead sponsor: Penn State University; Other
Eligibility: 35 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Dyslipidemia
Interventions: JTT-302, Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Santa Ana, California

Conditions: HIV Infections, Hypercholesterolemia, Hypertriglyceridemia, Diabetes Mellitus
Interventions: Niacin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 16
States / cities: Los Angeles, California • San Diego, California • Stanford, California + 8 more

Conditions: Cardiovascular Diseases, Coronary Disease, Heart Diseases, Coronary Arteriosclerosis
Interventions: Estrogens, Conjugated (USP), Medroxyprogesterone 17-Acetate, Placebo; Drug
Lead sponsor: Tufts University; Other
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 309 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Left Ventricular Hypertrophy
Interventions: Exercise training, women, marathon; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 187 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Metabolic Syndrome, Insulin Resistance
Interventions: TA-65, Placebo; Dietary Supplement
Lead sponsor: University of Connecticut; Other
Eligibility: 35 Years to 70 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Dyslipidemia
Interventions: Krill Oil, Lutein, Nicotinic acid, Dairy phospholipids, Control; Dietary Supplement · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Davis, California

Conditions: HDL Cholesterol
Interventions: Simvastatin, Atorvastatin 80 mg; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Homozygous Familial Hypercholesterolemia, HoFH
Interventions: HDL Therapeutics PDS-2 System; Device
Lead sponsor: HDL Therapeutics; Industry
Eligibility: 12 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Atherosclerosis, Coronary Artery Disease
Interventions: RVX000222, Placebo; Drug
Lead sponsor: Resverlogix Corp; Industry
Eligibility: 18 Years and older
Enrollment: 299 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Tustin, California

Conditions: Dyslipidemia, Atherosclerosis, Acute Coronary Syndrome, Cardiovascular Disease
Interventions: RVX000222, Placebo; Drug
Lead sponsor: Resverlogix Corp; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dyslipidemia
Interventions: Saturated Fat Diet; Dietary Supplement
Lead sponsor: UCSF Benioff Children's Hospital Oakland; Other
Eligibility: 18 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Type 2 Diabetes
Interventions: Peanuts and peanut butter; Dietary Supplement
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Hypertriglyceridemia
Interventions: Lovaza (Omega-3 acid ethyl esters), Placebo; Drug
Lead sponsor: University of Utah; Other
Eligibility: 35 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Lipid Metabolism, Inflammation
Interventions: Whole Eggs, Egg White-Based Egg Substitute; Other
Lead sponsor: Fairfield University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Fairfield, Connecticut

Conditions: Non-alcoholic Steatohepatitis, Hypertriglyceridemia, Non-alcoholic Fatty Liver Disease, Hypercholesterolemia
Interventions: MN-001; Drug
Lead sponsor: MediciNova; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Coronado, California • La Jolla, California • Seattle, Washington

Conditions: Obesity, Hypertension, Hypercholesterolemia, Hyperglycemia
Interventions: Metformin, Placebo; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 21 Years to 80 Years
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Obesity
Interventions: No experimental intervention will take place - the study is cross-sectional. Each participant will provide biological samples.; Other
Lead sponsor: Oklahoma State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 80 participants
Timeline: 2022
U.S. locations: 1
States / cities: Stillwater, Oklahoma

Conditions: Metabolic Syndrome X
Interventions: Freeze-dried Whole Grape Powder, Grape Powder Placebo; Other
Lead sponsor: University of Connecticut; Other
Eligibility: 30 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Type 1 Diabetes, Heart Disease
Interventions: Vitamin E, Dummy pills; Dietary Supplement · Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 30 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Prostate Cancer
Interventions: high performance liquid chromatography, laboratory biomarker analysis, mass spectrometry; Other
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 40 Years to 120 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Acute Coronary Syndrome
Interventions: Placebo, CER-001; Drug
Lead sponsor: Cerenis Therapeutics, SA; Industry
Eligibility: Up to 75 Years
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 24
States / cities: Huntsville, Alabama • Phoenix, Arizona • San Diego, California + 21 more

Conditions: Coronary Artery Disease, Atherosclerosis
Interventions: ACP-501; Drug
Lead sponsor: MedImmune LLC; Industry
Eligibility: 30 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Cardiovascular Disease
Interventions: Observation of SAA on apoB containing lipoproteins; Other
Lead sponsor: Lisa Tannock; Other
Eligibility: 40 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Lexington, Kentucky

Search by objective public record fields.

Effect of Soy on HDL-C Function, Central Blood Pressure, and Arterial Stiffness

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Niacin for Treatment of Elevated Cholesterol and Triglycerides in HIV-Infected Patients

Estrogen, HDL, and Coronary Heart Disease in Women

Impact of Physical Activity on Left Ventricular Mass and Lipid Metabolism

The Effects of the Telomerase Activator TA-65 on Insulin Resistance, Inflammation, and Metabolic Syndrome

Feeding Trial to Determine How Combinations of Different Dietary Bioactive Ingredients Influence High Density Lipoprotein (HDL) Metabolism

Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc)

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Clinical Trial for Dose Finding and Safety of RVX000222 in Subjects With Stable Coronary Artery Disease

Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol

Effect of Saturated Fat on Large Low-density Lipoprotein (LDL) and High-density Lipoprotein (HDL)

Effects of Peanut and Peanut Butter Consumption on Blood Lipids and Glycemic Control in Adults With Type 2 Diabetes

Effects of Lovaza on High Density Lipoprotein (HDL) Composition and Function in Hypertriglyceridemia

Egg Effects on the Immunomodulatory Properties of HDL

Open-Label Study To Evaluate MN-001 on HDL & Triglyceride in NASH & NAFLD Subjects

The Effects of Metformin on Blood Vessel Structure and Function

Gut Permeability-related Inflammation and Cardiovascular Disease Risk in Normal-weight and Metabolically Healthy Obesity

Effects of a Standardized Freeze-dried Grape Powder on High Density Lipoprotein (HDL) Function in Metabolic Syndrome

Haptoglobin Phenotype, Vitamin E and High-density Lipoprotein (HDL) Function in Type 1 Diabetes

Biomarker 11-dh-TXB2 in Blood and Urine Samples From Patients With Prostate Cancer and Healthy Volunteers

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial

Effect of ACP-501 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Subjects With Coronary Artery Disease

The Association of SAA With Apolipoprotein B Affects Cardiovascular Risk